Determining optimal maintenance schedules for adjuvant intravesical bacillus Calmette–Guerin immunotherapy in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86
   PubMed Web of Science ®Google Scholar
• Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013;63:234-41
   PubMed Web of Science ®Google Scholar
• Babjuk M, Burger M, Zigeuner R, et al. EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 2013;64:639-53
   PubMed Web of Science ®Google Scholar
• Böhle A, Bock PR. Intravesical bacille Calmette–Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004;63:682-6
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette–Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964-70
   PubMed Web of Science ®Google Scholar
• Malmström PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette–Guérin for non–muscle-invasive bladder cancer. Eur Urol 2009;56:247-56
   PubMed Web of Science ®Google Scholar
• Shelley MD, Kynaston H, Court J, et al. A systematic review of intravesical bacillus Calmette–Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 2001;88:209-16
   PubMed Web of Science ®Google Scholar
• Han RF, Pan JG. Can intravesical bacillus Calmette–Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006;67:1216-23
   PubMed Web of Science ®Google Scholar
• Shelley MD, Wilt TJ, Court J, et al. Intravesical bacillus Calmette–Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004;93:485-90
   PubMed Web of Science ®Google Scholar
• Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette–Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169:90-5
   PubMed Web of Science ®Google Scholar
• Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette–Guerin in the treatment of superficial bladder tumors. J Urol 1976;116:180-3
   PubMed Web of Science ®Google Scholar
• Oddens J, Brausi M, Sylvester R, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette–Guérin in intermediate-and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013;63:462-72
   PubMed Web of Science ®Google Scholar
• Martínez-Piñeiro L, Portillo JA, Fernández JM, et al. Maintenance therapy with 3-monthly bacillus Calmette–Guérin for 3 years is not superior to standard induction therapy in high-risk non–muscle-invasive urothelial bladder carcinoma: final results of randomised CUETO study 98013. Eur Urol 2015;68:256-62
   PubMed Web of Science ®Google Scholar
• Zhu S, Tang Y, Li K, et al. Optimal schedule of bacillus Calmette–Guerin for non-muscle-invasive bladder cancer: a meta-analysis of comparative studies. BMC Cancer 2013;13:1
   Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-2
   PubMedGoogle Scholar
• Higgins J, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88
   PubMedGoogle Scholar
• Keus F, Wetterslev J, Gluud C, et al. Robustness assessments are needed to reduce bias in meta-analyses that include zero-event randomized trials. Am J Gastroenterol 2009;104:546-51
   PubMed Web of Science ®Google Scholar
• Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105-24
   PubMed Web of Science ®Google Scholar
• Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011;64:163-71
   PubMed Web of Science ®Google Scholar
• Spiegelhalter DJ, Best NG, Carlin BP, et al. Bayesian measures of model complexity and fit. J R Stat Soc Series B Stat Methodol 2002;64:583-639
   Web of Science ®Google Scholar
• Song F, Altman DG, Glenny AM, et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003;326:472
   PubMed Web of Science ®Google Scholar
• Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette–Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000;163:1124-9
   PubMed Web of Science ®Google Scholar
• Palou J, Laguna P, Millan-Rodriguez F, et al. Control group and maintenance treatment with bacillus Calmette–Guerin for carcinoma in situ and/or high grade bladder tumors. J Urol 2001;165:1488-91
   PubMed Web of Science ®Google Scholar
• Badalament RA, Herr HW, Wong GY, et al. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette–Guérin therapy of superficial bladder cancer. J Clin Oncol 1987;5:441-9
   PubMed Web of Science ®Google Scholar
• Koga H, Ozono S, Tsushima T, et al. Maintenance intravesical bacillus Calmette–Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: Randomized controlled trial by the BCG Tokyo Strain Study Group. Int J Urol 2010;17:759-66
   PubMed Web of Science ®Google Scholar
• Hinotsu S, Akaza H, Naito S, et al. Maintenance therapy with bacillus Calmette–Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer. BJU Int 2011;108:187-95
   PubMed Web of Science ®Google Scholar
• Akaza H, Hinotsu S, Aso Y, et al. Bacillus Calmette–Guerin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. Cancer 1995;75:552-9
   PubMed Web of Science ®Google Scholar
• Brausi M, Oddens J, Sylvester R, et al. Side effects of bacillus Calmette–Guerin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol 2014;65:69-76
   PubMed Web of Science ®Google Scholar
• Yabusaki N, Komatsu H, Tago K, et al. [Intravesical instillation of bacillus Calmette–Guerin for superficial bladder carcinoma: study on significance of additional maintenance instillations of bacillus Calmette–Guerin]. Nihon Hinyōkika Gakkai Zasshi 1991;82:290-6
   PubMedGoogle Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264-9
   PubMed Web of Science ®Google Scholar
• Brausi M, Collette L, Kurth K, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 2002;41:523-31
   PubMed Web of Science ®Google Scholar
• Lamm DL. Carcinoma in situ. Urol Clin North Am 1992;19:499-508
   PubMed Web of Science ®Google Scholar
• Griffiths TR, Charlton M, Neal DE, et al. Treatment of carcinoma in situ with intravesical bacillus Calmette–Guerin without maintenance. J Urol 2002;167:2408-12
   PubMed Web of Science ®Google Scholar
• Shang PF, Kwong J, Wang ZP, et al. Intravesical bacillus Calmette–Guérin versus epirubicin for Ta and T1 bladder cancer. Cochrane Database Syst Rev 2011;CD006885:CD006885
   PubMed Web of Science ®Google Scholar
• Witjes JA, Palou J, Soloway M, et al. Clinical practice recommendations for the prevention and management of intravesical therapy–associated adverse events. Eur Urol 2008;7(Suppl):667-74
   Web of Science ®Google Scholar
• Palou J, Rodriguez-Villamil L, Andreu-Crespo A, et al. Intravesical treatment of severe bacillus Calmette–Guerin cystitis. Int Urol Nephrol 2001;33:485-9
   PubMedGoogle Scholar
• Falkensammer C, Gozzi C, Hager M, et al. Late occurrence of bilateral tuberculous-like epididymo-orchitis after intravesical bacille Calmette–Guerin therapy for superficial bladder carcinoma. Urology 2005;65:175
   PubMedGoogle Scholar
• Tinazzi E, Ficarra V, Simeoni S, et al. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int 2006;26:481-8
   PubMed Web of Science ®Google Scholar
• van der Meijden AP, Sylvester RJ, Oosterlinck W, et al. Maintenance bacillus Calmette–Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial. Eur Urol 2003;44:429-34
   PubMed Web of Science ®Google Scholar
• Oddens JR, Sylvester RJ, Brausi MA, et al. The effect of age on the efficacy of maintenance bacillus Calmette–Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911. Eur Urol 2014;66:694-701
   PubMed Web of Science ®Google Scholar
• Huncharek M, Kupelnick B. The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a metaanalytic comparison of chemotherapy versus bacilli Calmette–Guerin immunotherapy. Am J Clin Oncol 2004;27:522-8
   PubMed Web of Science ®Google Scholar
• Rentsch CA, Birkhäuser FD, Biot C, et al. Bacillus Calmette–Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. Eur Urol 2014;66:677-88
   PubMed Web of Science ®Google Scholar
• Sengiku A, Ito M, Miyazaki Y, et al. A prospective comparative study of intravesical bacillus Calmette–Guérin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer. J Urol 2013;190:50-4
   PubMed Web of Science ®Google Scholar